Clinical guidelines for ovarian cancer: the Korean Society of Gynecologic Oncology guidelines

Banghyun Lee, Suk Joon Chang, Byung Su Kwon, Joo Hyuk Son, Myong Cheol Lim, Yun Hwan Kim, Shin Wha Lee, Chel Hun Choi, Kyung Jin Eoh, Jung Yun Lee, Dong Hoon Suh, Yong Beom Kim

Research output: Contribution to journalArticlepeer-review

Abstract

Since the latest practice guidelines for ovarian cancer were developed by the Korean Society of Gynecologic Oncology (KSGO) in 2021, many studies have examined the efficacy and safety of various treatments for epithelial ovarian cancer (EOC). Therefore, the need to develop recommendations for EOC treatments has been raised. This study searched the literature using 4 key items and the Population, Intervention, Comparison, and Outcome: the efficacy and safety of poly-ADP ribose polymerase inhibitors in newly diagnosed advanced EOC; the efficacy and safety of intraperitoneal plus intravenous chemotherapy in optimally debulked advanced EOC; the efficacy and safety of secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer; and the efficacy and safety of the addition of bevacizumab to platinum-based chemotherapy in first platinum-sensitive recurrent EOC patients who received prior bevacizumab. The evidence for these recommendations, according to each key question, was evaluated using a systematic review and meta-analysis. The committee of ovarian cancer of the KSGO developed updated guidelines for treatments of EOC.

Original languageEnglish
Article numbere43
JournalJournal of Gynecologic Oncology
Volume35
Issue number1
DOIs
StatePublished - Jan 2024

Bibliographical note

Publisher Copyright:
© 2024. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.

Keywords

  • Bevacizumab
  • Cytoreductive Surgery
  • Epithelial Ovarian Cancer
  • Intraperitoneal Chemotherapy
  • Poly (ADP-ribose) Polymerase Inhibitor
  • Survival

Fingerprint

Dive into the research topics of 'Clinical guidelines for ovarian cancer: the Korean Society of Gynecologic Oncology guidelines'. Together they form a unique fingerprint.

Cite this